New Targeted Drugs Show Promise for BCG-Resistant Bladder Cancer Patients
A narrative review finds erdafitinib and other targeted therapies may help patients avoid radical bladder removal after BCG treatment fails.
Summary
When bladder cancer stops responding to the standard BCG immunotherapy, patients typically face surgical bladder removal — a major operation with lasting quality-of-life consequences. This narrative review examines whether targeted drugs can bridge the gap. The THOR-2 trial found that the oral FGFR inhibitor erdafitinib kept 77% of high-risk patients recurrence-free at 12 months, though every patient experienced side effects. Three other phase II trials testing dovitinib, sunitinib, and everolimus showed more modest results, with disease-free survival ranging from 8 to 44%. Meanwhile, a phase 3 trial of oportuzumab monatox — an EpCAM-targeting drug — achieved a 40% complete response rate at three months with responses lasting nearly 10 months on average. These results suggest targeted therapy could delay or prevent cystectomy for select patients.
Detailed Summary
Bladder cancer that fails to respond to BCG immunotherapy represents one of urology's most challenging clinical dilemmas. The standard next step — radical cystectomy — carries significant morbidity and permanently alters patient quality of life. There is urgent need for effective bladder-sparing alternatives, making this review timely and clinically important.
The authors compiled evidence from multiple trials evaluating targeted therapies in patients with BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC). The agents reviewed act on distinct molecular pathways: FGFR inhibitors (erdafitinib, dovitinib), a VEGF inhibitor (sunitinib), an mTOR inhibitor (everolimus), and an EpCAM-targeted immunotoxin (oportuzumab monatox).
The standout data came from the THOR-2 study, in which 73 high-risk patients with pTa/pT1 disease received oral erdafitinib. Recurrence-free survival reached 96% at 6 months and 77% at 12 months — impressive figures in a population that historically faces early progression. However, all 73 patients experienced adverse events, with 22% classified as serious, raising important tolerability questions. The three phase II trials of dovitinib, sunitinib, and everolimus produced more modest disease-free survival rates of 8–44% over 3–12 months, suggesting variable efficacy across pathway targets. Oportuzumab monatox, tested in a phase 3 trial of 134 patients, delivered a 40% complete response rate at 3 months and a median response duration of 9.4 months — clinically meaningful in this context.
The findings collectively suggest that molecular targeting of FGFR alterations in particular may offer a viable bladder-preservation strategy in appropriately selected patients. Patient selection based on tumor molecular profile — especially FGFR mutation status — may prove critical.
Key caveats include the narrative review design, small trial sample sizes, short follow-up durations, and the absence of head-to-head comparisons. The high adverse event burden of erdafitinib also warrants careful risk-benefit assessment in clinical practice.
Key Findings
- Erdafitinib (THOR-2) achieved 77% recurrence-free survival at 12 months in high-risk BCG-unresponsive NMIBC patients.
- All patients receiving erdafitinib experienced adverse events; 22% had serious events requiring clinical attention.
- Oportuzumab monatox produced a 40% complete response rate with median response duration of 9.4 months in a phase 3 trial.
- Dovitinib, sunitinib, and everolimus showed modest disease-free survival of 8–44% across phase II studies.
- Targeted therapies may delay or replace radical cystectomy in select BCG-unresponsive NMIBC patients.
Methodology
This is a narrative review synthesizing evidence from multiple clinical trials including one phase 3 trial, three phase II trials, and the THOR-2 study cohort. Sample sizes were small, ranging from 73 to 134 patients. Follow-up durations varied from 3 to 12 months across studies, limiting long-term conclusions.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. As a narrative review, findings are subject to selection bias and lack quantitative meta-analytic pooling. Small trial sizes, short follow-up periods, and absence of direct comparisons between agents limit the strength of conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: